A blog about research, awareness, prevention, treatment and survivorship of Breast Cancer and all cancers, including targeted scientific research and a grassroots approach to increase screening for cancer, especially in the low income and under-insured population of El Paso, Texas, with a view to expand this new health care model to many other 'minority' populations across the United States and beyond
Wednesday, August 13, 2014
Keep on asking myself!
"Lucitanib has 50% Response (PR) in FGF-amplified Breast Cancer"
given FGF amplification requirement, and the involvement of Heparan sulfate the great cover of receptor, how this drug may interact with Hormone replacement therapy?
No comments:
Post a Comment